Updated Jul 16, 2007 at 23:14 EST.
Plethora Solutions Holding PLC provided an update for the inhaled treatment PSD502 being developed to treat premature ejaculation ( PE ). The company states that a completed clinical study indicates that PSD502 is a viable treatment for premature ejaculation ( PE ). The medication is well tolerated and thus far, no noticeable side effects have been observed.
PSD502 could be the first inhaled treatment developed specifically to treat premature ejaculation ( PE ). The trial indicates that men using it could experience a rapid onset of less than 5 minutes. The drug lasts up to 2 hours giving ample opportunity for sexual activity without the couple feeling that medication is disruptive to their love life.
Written by the PEhomepage.com Editorial Team.
Back to Articles 
Latest News Archive 
E-mail a Friend
